The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Inhibrx Biosciences Inc shares valued at $991,416 were purchased by Kayyem Jon Faiz on Nov 19 ’24. At $14.23 per share, Kayyem Jon Faiz acquired 69,686 shares. The insider’s holdings grew to 51,093 shares worth approximately $0.77 million following the completion of this transaction.
Also, Kayyem Jon Faiz purchased 37,500 shares, netting a total of over 532,204 in proceeds. Following the buying of shares at $14.19 each, the insider now holds 69,843 shares.
Before that, Lappe Mark had added 26,963 shares to its account. In a trade valued at $405,793, the Chief Executive Officer bought Inhibrx Biosciences Inc shares for $15.05 each. Upon closing the transaction, the insider’s holdings increased to 26,963 shares, worth approximately $10.37 million.
As published in their initiating research note from JMP Securities on July 23, 2024, Inhibrx Biosciences Inc [INBX] has been a Mkt perform.
Analyzing INBX Stock Performance
During the last five days, there has been a drop of approximately -2.73%. Over the course of the year, Inhibrx Biosciences Inc shares have dropped approximately -2.73%. Nevertheless, trading volume fell to 59093.0 shares from 38000.0 shares the previous day.
Support And Resistance Levels for Inhibrx Biosciences Inc (INBX)
According to the 24-hour chart, there is a support level at 14.57, which, if violated, would cause prices to drop to 14.17. In the upper region, resistance lies at 15.59. The next price resistance is at 16.21. RSI (Relative Strength Index) is 48.50 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.64, which suggests the price will decrease in the coming days. Percent R is at 55.72%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
